Zimmer Biomet Holdings Inc (NYSE:ZBH) Stock Holdings Reduced by Rothschild Investment Corp IL

Rothschild Investment Corp IL lowered its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 95.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,498 shares of the medical equipment provider’s stock after selling 81,709 shares during the quarter. Rothschild Investment Corp IL’s holdings in Zimmer Biomet were worth $480,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Personal Wealth Partners purchased a new position in Zimmer Biomet in the second quarter valued at about $26,000. TRUE Private Wealth Advisors purchased a new position in Zimmer Biomet in the second quarter valued at about $26,000. Allworth Financial LP grew its stake in Zimmer Biomet by 65.0% in the third quarter. Allworth Financial LP now owns 203 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 80 shares in the last quarter. Coastal Investment Advisors Inc. grew its stake in Zimmer Biomet by 271.0% in the second quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 187 shares in the last quarter. Finally, Private Ocean LLC grew its stake in Zimmer Biomet by 34.8% in the second quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 87.83% of the company’s stock.

NYSE ZBH opened at $136.44 on Friday. Zimmer Biomet Holdings Inc has a twelve month low of $96.99 and a twelve month high of $143.57. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 1.19. The stock has a market capitalization of $27.39 billion, a PE ratio of 17.86, a P/E/G ratio of 2.53 and a beta of 1.16. The stock has a 50-day simple moving average of $137.14 and a 200 day simple moving average of $127.13.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.02. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The business had revenue of $1.99 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the previous year, the firm earned $1.92 EPS. The firm’s revenue was down .9% compared to the same quarter last year. As a group, equities research analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Friday, September 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.70%. Zimmer Biomet’s dividend payout ratio is presently 12.57%.

Several analysts have recently issued reports on the company. Raymond James upped their price target on Zimmer Biomet from $145.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, July 29th. Stifel Nicolaus set a $155.00 price target on Zimmer Biomet and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Credit Suisse Group upped their price target on Zimmer Biomet from $101.00 to $120.00 and gave the stock an “underperform” rating in a research note on Monday, July 29th. Canaccord Genuity upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and upped their price target for the stock from $137.00 to $167.00 in a research note on Wednesday, September 18th. Finally, Barclays upgraded Zimmer Biomet from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $117.00 to $140.00 in a research note on Tuesday, July 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $145.40.

In other Zimmer Biomet news, insider Didier Deltort sold 360 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $139.25, for a total value of $50,130.00. Following the completion of the transaction, the insider now owns 1,194 shares of the company’s stock, valued at approximately $166,264.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Chad F. Phipps sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $138.28, for a total value of $967,960.00. Following the completion of the transaction, the vice president now directly owns 37,722 shares of the company’s stock, valued at approximately $5,216,198.16. The disclosure for this sale can be found here. Insiders have sold a total of 40,391 shares of company stock valued at $5,642,274 in the last three months. 0.72% of the stock is owned by insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: Penny Stocks, Risk and Reward Factors

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.